Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

We have 17 Pharmacology (tumour) PhD Projects, Programmes & Scholarships

Discipline

Discipline

Medicine

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


Pharmacology (tumour) PhD Projects, Programmes & Scholarships

We have 17 Pharmacology (tumour) PhD Projects, Programmes & Scholarships

(MRC DTP CASE) Understanding how tumour associated macrophages control the tumour immune landscape in NF2-Schwannomatosis

Type 2 Neurofibromatosis (NF2), now referred to as NF2-Schwannomatosis (or NF2-SWN), is a rare autosomal dominant tumour pre-disposition syndrome characterised by growth of typically benign tumours throughout the nervous system. Read more

Personalising cancer treatment with tumour evolution modelling using AI-based genomics biomarkers and PK/PD

Tumour heterogeneity is a major problem limiting the efficacy of targeted oncological therapies. Most advanced tumours eventually become resistant to the treatments, ultimately making the patient succumb to metastatic disease. Read more

Design, synthesis and evaluation of protease-activated anti-cancer prodrugs

  Research Group: Institute of Cancer Therapeutics
Matrix metalloproteinases (MMPs) are a family of endoproteases that are overexpressed in tumours and play crucial roles in many tumourigenic processes, not least tumour invasion and angiogenesis. Read more

Vascularisation of tumour organoids for mechanistic and drug development

Gliomas such as are the most common form of brain tumour, a subset Glioblastoma (GBM) are devastating adult brain cancer with high rates of recurrence and treatment resistance. Read more

Transcriptome biomarkers and mechanisms of chemoresistance

Project Summary. This project aims to identify biomarkers linked to the most potent multimodal anticancer therapy with the least toxicity to counteract hemoresistance in head and neck squamous cell carcinoma (HNSCC). Read more

Mechanisms of Cancer Stem Cell Survival, Metastasis Formation and Immune Evasion in Cancer

Recent research suggests that cancer cells within a tumour represent a highly heterogeneous cell population. In particular many tumours contain small percentage of cells that share several characteristics with stem cells. Read more

Postgraduate Research Opportunities at the Faculty of Medicine and Dentistry

To deliver our research strategy of ‘Better Health for All' and our aspiration to train the research leaders of the future, the Faculty of Medicine and Dentistry (top 10% faculties of medicine in the world, QS2022) has opened opportunities for self-funded PhD students in multiple areas of biomedical and translational research across six internationally recognised Research Institutes. Read more

Investigating how dormant senescent cells can drive drug-resistance following chemotherapy

Most anti-cancer chemotherapeutics work by inducing DNA damage and arresting the cell cycle in either G1 or G2 phase. A frequent outcome of this arrest is that cells exit the cell cycle into a state known as senescence. Read more

Pharmacokinetics Guided Natural Products Exploration for Drug Discovery, Development, Delivery and Therapy

  Research Group: Institute of Cancer Therapeutics
Natural products have emerged as a key standard in novel and safe delivery of anticancer bioactive compounds. Apart from their ease of administration and delivery, natural/phytochemicals still face several hurdles, due to their physiochemical and pharmacokinetic properties. Read more

New Drugs for Brain Tumours: A Locoregional Implant Brain Tumours

  Research Group: Medicines Development and Pharmaceutical Sciences
Next-generation temozolomide derivatives for the treatment of high-grade glioma have been developed at the University of Bradford. Read more

Development of antibody-drug conjugates (ADCs) for oncology indications

  Research Group: Institute of Cancer Therapeutics
A major challenge in cancer therapy is to develop therapeutic agents that selectively target tumour cells but are not harmful to normal tissue. Read more

Filtering Results